findmyKOL
Clinical trialNCT05722418RecruitingPhase 1Interventional

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

SponsorCaribou Biosciences, Inc.Enrollment50Relapsed/Refractory Multiple Myeloma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

    Recruiting
  • Cu Anschutz Medical Campus, Anshutz Cancer Pavillion

    Aurora, Colorado, United States

    Daniel Sherbenou, MD, PhD
    Recruiting
  • Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics

    Miami, Florida, United States

    Jay Spiegel, MD
    Recruiting
  • University of Kentucky/ Markey Cancer Center

    Lexington, Kentucky, United States

    Gregory Monohan, MD
    Recruiting
  • Hackensack Meridian John Theurer Cancer Center

    Hackensack, New Jersey, United States

    David Siegal, MD
    Recruiting
  • Icahn School of Medicine at Mount Sinai

    New York, New York, United States

    Adriana Rossi, MD
    Recruiting
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Sham Mailankody, MBBS
    Recruiting
  • Levine Cancer Institute

    Charlotte, North Carolina, United States

    Manisha Bhutani, MD
    Recruiting
  • Duke University Health System (duhs)

    Durham, North Carolina, United States

    Cristina Gasparetto, MD
    Recruiting
  • Oncology Hematology Care, Inc

    Cincinnati, Ohio, United States

    James Essell, MD
    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, United States

    Faiz Anwer, MD
    Recruiting
  • Tennessee Oncology

    Nashville, Tennessee, United States

    Jesus Berdeja, MD
    Recruiting
  • University of Texas Southwestern Medical Center

    Dallas, Texas, United States

    Larry Anderson, MD
    Recruiting
  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah, United States

    Douglas Sborov, MD
    Recruiting
  • Virginia Commonwealth University

    Richmond, Virginia, United States

    William Clark, MD
    Recruiting
  • Froedtert and the Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

    Binod Dhakal, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Feb 2023
Primary completion
31 Dec 2027
Completion
31 Dec 2027
Last update posted
25 Sept 2025
Registered enrollment
50
Registry id
NCT05722418

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.